Clinton Names New NCI Director

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

WASHINGTON--President Clinton has appointed Dr. Richard D. Klausner as director of the National Cancer Institute. Dr. Klausner has served as chief, Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, since 1984. He earned his undergraduate degree at Yale and his MD from Duke.

WASHINGTON--President Clinton has appointed Dr. Richard D. Klausneras director of the National Cancer Institute. Dr. Klausner hasserved as chief, Cell Biology and Metabolism Branch, NationalInstitute of Child Health and Human Development, since 1984. Heearned his undergraduate degree at Yale and his MD from Duke.

In a statement of congratulations from the American Society ofClinical Oncology, John H. Glick, MD, president, called Dr. Klausnera "distinguished molecular biologist . . . with an impressiverecord of scientific and administrative accomplishments at theNIH."

Dr. Harold E. Varmus, NIH director, said that Dr. Klausner "bringsto this important post an extraordinary record of scientific achievement,admirable personal qualities, and a firm commitment to advancingthe nation's health through vigorous and innovative science. Iam sure that Dr. Klausner will provide the leadership that NIH'slargest and most visible institute needs as it carries forwardthe fight against cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.